# 1 Children and Adolescent Patients with Variants in the *ATP1A3*-encoded Sodium-Potassium ATPase<br>2 Alpha-3 Subunit Demonstrate an Impaired QT Response to Bradycardia and Predisposition to Sinus No 2 Alpha-3 Subunit Demonstrate an Impaired QT Response to Bradycardia and Predisposition to Sinus Node **Dysfunction**  $\frac{4}{5}$

### 5 Short Title: Abnormal QT and QTc Dynamics in AHC

 $\frac{6}{7}$ 7 Meredith K. Srour, BA<sup>1</sup>; Minu-Tshyeto K. Bidzimou, BA<sup>1,2</sup>; Padmapriya Muralidharan, PhD<sup>1</sup>; Saige M. 8 Mitchell, BS<sup>1</sup>; Mary E. Moya-Mendez, MD<sup>1</sup>; Lauren E. Parker, BS<sup>1</sup>; Gabriela Reyes Valenzuela, MD<sup>3</sup>; 9 Roberto Caraballo, MD<sup>3</sup>; Giacomo Garone, MD<sup>4</sup>; Federico Vigevano, MD<sup>4</sup>; Sarah Weckhuysen, MD 10 PhD<sup>5,6,7</sup>; Charissa Millevert, MD<sup>5,6</sup>; Monica Troncoso, MD<sup>8</sup>; Mario Matamala, MD<sup>8</sup>; Simona Balestrini, 11 MD PhD<sup>9,10</sup>; Sanjay M. Sisodiya, PhD FRCP<sup>9</sup>; Josephine Poole, MSc<sup>9</sup>; Claudio Zucca, MD<sup>11</sup>; Eleni Panagiotakaki, MD PhD<sup>12</sup>; Maria T. Papadopoulou, MD<sup>12</sup>; Sébile Tchaicha, MS<sup>12,14</sup>; Matthildi Athina Papathanasiou Terzi<sup>12</sup>; Marta Zawadzka, MD PhD<sup>13</sup>; Maria Mazurkiewicz-Bełdzińska, MD<sup>13</sup>; Carmen<br>14 Fons, MD PhD<sup>14</sup>; Jennifer Anticona, MD<sup>14</sup>; Elisa De Grandis, MD<sup>15,16</sup>; Ramona Cordani, MD<sup>15,16</sup>; Livia 14 Fons, MD PhD<sup>14</sup>; Jennifer Anticona, MD<sup>14</sup>; Elisa De Grandis, MD<sup>15,16</sup>; Ramona Cordani, MD<sup>15,16</sup>; Livia 15 Pisciotta, MD, PhD<sup>17</sup>; Sergiu Groppa, MD<sup>18</sup>; Sandra Paryjas, MD<sup>18</sup>; Francesca Ragona, MD<sup>19</sup>; Elena 16 Mangia, RN<sup>19</sup>; Tiziana Granata, MD<sup>19</sup>; Andrey Megvinov, PhD<sup>20</sup>; Rosaria Vavassori, PhD<sup>20,21,22</sup>;

- 17 Mohamad A. Mikati, MD<sup>23</sup>; Andrew P. Landstrom, MD, PhD<sup>1,2#</sup>
- 18
- 19
- <sup>1</sup>Department of Pediatrics, Division of Cardiology, Duke University School of Medicine, Durham, North<br>21 Carolina, United States. 21 Carolina, United States.<br>22 <sup>2</sup>Department of Cell Bi
- <sup>2</sup>Department of Cell Biology, Duke University School of Medicine, Durham, North Carolina, United<br>23 States. 23 States.<br>24  $\frac{3}{1}$ Hospi
- $3$ Hospital Nacional de Pediatría Juan P. Garrahan, Buenos Aires, Argentina
- 25 <sup>4</sup> Division of Neurology, Bambino Gesù Children's Hospital, Rome, Italy
- <sup>5</sup> 26 <sup>5</sup> Department of Neurology, Antwerp University Hospital, Antwerp, Belgium <sup>6</sup> Applied & Translational Neurogenomics Group, VIB Center for Molecular
- <sup>6</sup> <sup>6</sup> Applied & Translational Neurogenomics Group, VIB Center for Molecular Neurology, VIB, Antwerp, 28 Belgium 28 Belgium<br>29  $\frac{7}{1}$ Translat
- <sup>7</sup> Translational Neurosciences, Faculty of Medicine and Health Science, University of Antwerp, Antwerp, 30 Belgium 30 Belgium<br>31  $8$ Child No
- <sup>8</sup> Child Neurology Service, Hospital San Borja Arriarán, University of Chile, Santiago, Chile
- <sup>9</sup> Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, London
- 33 WC1N 3BG and Chalfont Centre for Epilepsy, London, Bucks, United Kingdom<br>34 <sup>10</sup>Neuroscience Department, Meyer Children's Hospital, European Reference N <sup>10</sup> Neuroscience Department, Meyer Children's Hospital, European Reference Network ERN EpiCARE, 35 50139, Florence, Italy
- <sup>11</sup> 36 <sup>11</sup> Clinical Neurophysiology Unit, IRCCS "E. Medea", Via Don L. Monza 20, 23842<br>37 Bosisio Parini (LC), Italy 37 Bosisio Parini (LC), Italy<br> $38$ <sup>12</sup>Department of Paediatri
- <sup>12</sup> Department of Paediatric Clinical Epileptology, Sleep Disorders and Functional Neurology, University<br>
139 Hospitals of Lyon, Member of ERN EpiCARE, France 39 Hospitals of Lyon, Member of ERN EpiCARE, France
- 40 <sup>13</sup>Department of Developmental Neurology, Medical University of Gdansk, ul. Debinki 7, 80-952, 41 Gdansk, Poland
- <sup>14</sup> Pediatric Neurology Department, Hospital Sant Joan de Déu, Full Member of ERN EpiCare, Barcelona<br>43 University, Institut de Recerca Sant Joan de Déu, Barcelona, Spain
- 43 University, Institut de Recerca Sant Joan de Déu, Barcelona, Spain<br>44 <sup>15</sup>Child Neuropsychiatry Unit, IRCCS Istituto Giannina Gaslini, Ge
- <sup>15</sup> 44 <sup>15</sup> Child Neuropsychiatry Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy <sup>16</sup> Department of Neurosciences, Rehabilitation, Ophtalmology, Genetics,
- <sup>16</sup>Department of Neurosciences, Rehabilitation, Ophtalmology, Genetics, Maternal and Child Health
- 46 (DiNOGMI), University of Genoa, Genoa, Italy
- <sup>17</sup> Unit of Child Neuropsychiatry, ASST Fatebenefratelli Sacco, Milan, Italy
- <sup>18</sup> 48 Clinic of Neurology, Johannes Gutenberg University of Mainz, Mainz, Germany
- <sup>19</sup> 49 Department of Pediatric Neuroscience, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan,
- 50 Italy; Member of ERN EpiCARE, Via Celoria 11, 20133 Milan, Italy

- <sup>20</sup> Euro-Mediterranean Institute of Science and Technology (I.E.ME.S.T.), Palermo, Italy; Informatics<br>52 Department www.iemest.eu
- Department www.iemest.eu
- $211$   $\text{AHCRC}$  International Research Consortium, Data Management www.iahcrc.net  $22$  European Reference Network EpiCARE-ERN, Patient Advocacy Group (ePAG) v
- <sup>22</sup> European Reference Network EpiCARE-ERN, Patient Advocacy Group (ePAG) www.epi-care.eu<br>55 <sup>23</sup> Department of Pediatrics, Division of Neurology, Duke University School of Medicine, Durham,
- <sup>23</sup> Department of Pediatrics, Division of Neurology, Duke University School of Medicine, Durham, North<br>56 Carolina, United States.
- Carolina, United States.
- 57
- 58 #Corresponding Author:<br>59 Andrew P. Landstrom, M
- 59 Andrew P. Landstrom, MD, PhD
- 60 Duke University Medical Center
- 61 Box 2652
- 62 Durham, North Carolina, 27710
- 63 United States
- 64 Email: andrew.landstrom@duke.edu
- 65 Phone: (919) 684-3028 Fax: (919) 385-9329<br>66 Word Count: 3895
- Word Count: 3895

### 67 **ABSTRACT**

68 Background: Alternating hemiplegia of childhood (AHC) is a rare disorder with both neurologic and 69 cardiac manifestations. The ATP1A3-D801N variant is associated with a pathologically short QT interval 70 and risk of ventricular arrhythmia following bradycardia; however, the mechanism of this remains 71 unknown. We investigated the relationship between heart rate (HR), QT, and QTc, hypothesizing that 72 individuals with ATP1A3-D801N have abnormal, impaired shortening of QT and QTc at lower HR 73 leading to arrhythmia predisposition.

74 Methods: We performed a retrospective observational study of individuals who underwent clinical 75 evaluation, Holter monitoring, and genetic testing for AHC at Duke University Hospitals. We also 76 compiled a group of healthy individuals as a control cohort. A larger, worldwide cohort of individuals 77 with *ATP1A3*-related phenotypes was compiled to investigate sinus node dysfunction. Linear regression 78 analysis was then performed.

79 Results: The cohort consisted of 44 individuals with *ATP1A3*-related phenotypes with 81 Holter 80 recordings (52.27% female; mean age at first Holter 8.04 years, range 0.58 – 33 years), compared to 36 81 healthy individuals with 57 Holter recordings (52.78% female; mean age at first Holter 9.84 years, range 82 0.08 – 38 years). Individuals with ATP1A3-D801N had reduced prolongation of QT at lower HR, 83 manifest as a significantly lower slope for HR vs QT compared to healthy (P<0.0001). This resulted in a 84 significantly higher slope of the relationship for HR vs QTc compared to healthy (P<0.0001). Individuals 85 with *ATP1A3*-related phenotypes and baseline QTc <350 milliseconds (ms) had increased shortening of 86 QT and QTc at lower HR compared to those with normal QTc (P=0.003; P=0.001). Among worldwide 87 cases, 3 out of 131 individuals with *ATP1A3*-related phenotypes required device implantation and/or had 88 sinus pauses > 4 seconds.

89 Conclusions: Individuals with the ATP1A3-D801N variant exhibit paradoxical shortening of QT and QTc 90 at lower HR, which contributes to an increased risk of arrhythmias during bradycardia. This is 91 exacerbated by an underlying risk of sinus node dysfunction.

92

# 93 Non-Standard Abbreviations and Acronyms

- 94 AHC: alternating hemiplegia of childhood
- 95 *ATP1A3*: gene encoding for the alpha-3 subunit of sodium-potassium ATPase
- 96 ATP1A3-D801N: D801N missense variant in *ATP1A3*-encoded ATP1A3
- 97 ATP1A3 Non-D801N: missense single nucleotide variants, not including D801N, in *ATP1A3*-encoded
- 98 ATP1A3
- 99 *ATP1A3* LOF: presumed loss of function variants in *ATP1A3*-encoded ATP1A3
- 100 *ATP1A3* Neg: no pathogenic or likely pathogenic variant identified in *ATP1A3*
- 101 QTc: corrected QT interval
- 102 HR: heart rate
- 103 BPM: beats per minute
- 104 SUDEP: sudden unexplained death in epilepsy
- 105
- 106
- 107 Clinical Perspective:
- 108 What is Known:
- 109 Individuals with ATP1A3-D801N have a short baseline QTc.
- 110 Two individuals with AHC experienced ventricular fibrillation following bradycardia.
- 111 What the Study Adds:
- **112** The QT and QTc shorten to a greater extent at lower heart rate in individuals with ATP1A3-
- 113 D801N than in healthy individuals.
- 114 Individuals with *ATP1A3*-related phenotypes and QTc <350ms show greater impairment of QT 115 and QTc dynamics than those with normal QTc.
- 116 There is low prevalence of device implantation and significant sinus pauses in individuals with
- 117 *ATP1A3*-related phenotypes, with a relatively greater prevalence in those with ATP1A3-D801N.

# 118 **INTRODUCTION**

119 Individuals with abnormally fast cardiac repolarization, manifest as a shortened QT interval, are at an 120 increased risk of atrial and ventricular arrhythmias which can be life-threatening<sup>1-3</sup>. As heart rate (HR) 121 can modulate QT interval, diagnostic criteria center around a corrected QT (QTc) which measures 122 ventricular repolarization and normalizes it to heart rate, often using Bazett's correction<sup>4,5</sup>. A diagnosis of 123 short QT syndrome (SQTS) uses Gollob's criteria, a point-based diagnostic system with increasing points 124 given for QTc <370, <350, and <330ms, respectively<sup>6</sup>. In addition to short QTc, SQTS can also present 125 with sinus node dysfunction, with prior case reports describing episodes of sinus arrest and junctional 126 rhythm<sup>7,8</sup>. Further, there is an emerging relationship between HR and QT response in SQTS. Prior work 127 has shown that individuals with SQTS display blunted response of QT to changes in HR when compared 128 to healthy individuals<sup>9-11</sup>. However, the genetic and mechanistic causes of SOTS are often unclear. While 129 believed to be heritable, only a minority of patients with SQTS are genotype positive for causative 130 genes<sup>2,12</sup>. Thus, there is a need to identify new genes and new mechanisms of SQTS development.

131 Alternating hemiplegia of childhood (AHC) is a rare condition which typically manifests prior to 132 18 months of age with episodic hemiplegia and/or quadriplegia, dystonia, oculomotor abnormalities, 133 seizures, dysautonomia, and sudden unexplained death in epilepsy (SUDEP)<sup>13,14</sup>. We have previously 134 found that individuals with AHC have cardiac features that are similar to those with SQTS, including a 135 shortened QTc on electrocardiogram  $(ECG)^{15-18}$  and sinus node dysfunction that may require device 136 implantation<sup>19,20</sup>. Specifically, we found that individuals hosting ATP1A3-D801N, the most common 137 missense variant among those with AHC, are uniquely predisposed to short QTc interval and ventricular 138 arrhythmias associated with bradycardia, particularly during periods of anesthesia or sedation<sup>15,18,21,22</sup>. 139 Taken together, this work suggests that SUDEP in AHC is due to the short QT phenotype; however, the 140 link between bradycardia and arrhythmia generation remains unknown. Exploring this question will yield 141 important new insight into SQTS, and the modulators of cardiac repolarization, more broadly.

142 With this in mind, we sought to investigate QT and QTc dynamics in AHC with respect to HR 143 through linear regression analysis, which has been previously utilized for this purpose<sup>9,23-27</sup>. We evaluated

144 cardiac Holter recordings of individuals with AHC and healthy individuals to determine QT and QTc 145 responses to HR and expand our understanding of arrhythmogenic risk in ATP1A3-D801N. Finally, we 146 convened a worldwide cohort of AHC cases to determine the risk of sinus node dysfunction and 147 associated outcomes.

148

### 149 **METHODS**

150 This was a retrospective study approved by the Duke University Hospitals Institutional Review Board, 151 IRB #Pro00094341. Informed consent was waived. In addition, retrospective data on AHC patients was 152 obtained using the International Consortium for Research on AHC and all the *ATP1A3* Rare Diseases 153 (IAHCRC), according to the rules of the IAHCRC Charter. All sites had ethics board or IRB approval.

154

- 155 Cohorts
- 156 Primary Cohort

157 The primary cohort consisted of consecutively enrolled individuals seen at Duke University Hospitals 158 who had undergone clinical evaluation and genetic testing for AHC. Individuals were included if they 1) 159 met full Aicardi diagnostic criteria for  $AHC^{13}$ , 2) met atypical/partial AHC diagnostic criteria and, 3) 160 were diagnosed with cerebellar ataxia, areflexia, pes cavus, optic atrophy, and sensorineural deafness 161 (CAPOS), another disorder associated with *ATP1A3* mutations<sup>17</sup>. Individuals were excluded if they did 162 not have 1) a reported ECG, or 2) an ambulatory Holter monitoring report using HScribe<sup>TM</sup> software. 163 Individuals in this cohort were further categorized based on genotype as follows: ATP1A3-D801N; other 164 pathogenic or likely pathogenic single nucleotide variant in *ATP1A3*, defined as ATP1A3 non-D801N; 165 presumed loss of function variant in *ATP1A3* such as deletion or splice site variant, defined as *ATP1A3* 166 LOF; and no likely pathogenic or pathogenic *ATP1A3* variant detected on genetic testing, defined as 167 genotype negative or *ATP1A3* Neg.

168

169 Healthy Cohort

170 Healthy individuals were selected for a comparison cohort if they were seen at Duke University Hospitals 171 for a cardiovascular evaluation. The following individuals were excluded: 1) elite athletes with 172 documented cardiovascular changes secondary to intense cardiovascular activity; 2) those with known 173 congenital heart disease, channelopathy, cardiomyopathy, and skeletal myopathy; 3) those with known 174 genetic syndrome with cardiac phenotype; 4) those taking cardiac medications, including antiarrhythmics; 175 5) those with an abnormal ECG and/or echocardiogram; and 6) those with ventricular or supraventricular 176 ectopy >1% of total QRS complexes on Holter recording. All healthy individuals had undergone Holter 177 monitoring with HScribe<sup>TM</sup> software following cardiology visits for risk prediction due to identification of 178 a genetic variant associated with cardiac disease, family history of sudden cardiac arrest, cardiomyopathy, 179 and/or channelopathy, or history of arrhythmias or prolonged QT that had since resolved. Healthy 180 individuals were matched to AHC individuals based on sex and age (+/- 2 years).

181

#### 182 IAHCRC Cohort

183 Given the rarity of AHC diagnoses, a multinational rare disease registry was established which consisted 184 of individuals from Duke University Hospitals as above, the IAHCRC, and the Baylor College of 185 Medicine (BCM). The cohort from the IAHCRC has been previously described<sup>28</sup>. Inclusion criteria for 186 these individuals included, 1) meeting full Aicardi diagnostic criteria for AHC as diagnosed by a 187 neurologist<sup>13</sup>, 2) meeting atypical/partial AHC diagnostic criteria, and 3) meeting criteria for other 188 diagnoses, such as rapid-onset dystonia-parkinsonism (RDP) or CAPOS, if they had a confirmed variant 189 in *ATP1A3*<sup>28</sup>. Individuals were excluded from analysis if they 1) did not meet the inclusion criteria, 2) did 190 not have outcome data available, such as survival and pacemaker (PM) or PM/implantable cardioverter 191 defibrillator (ICD) implantation, and 3) did not have at least 1 ECG with original tracings available for re-192 review.

193

### 194 Holter Data Analysis

195 Holter data was collected from the Primary Cohort and Healthy Cohort using the HScribe<sup>TM</sup> cardiac 196 monitoring software. Holter recordings ranged in duration from 45 minutes to 24 hours. Automatically 197 generated minimum, mean, and maximum HR, QT, and QTc measurements over 5-minute intervals 198 throughout the Holter recording were abstracted. QTc was calculated using Bazett's correction<sup>5</sup>. A linear 199 regression analysis was performed for each Holter recording and genotype, and a line of fit equation was 200 calculated. Automated QT or QTc measurements that appeared to be outliers on visual inspection of 201 linear regression and were greater than 1.5 times the value of the line of fit equation for a given HR were 202 remeasured manually using Lepeschkin's method and Bazett's correction<sup>5,29</sup> and were excluded if they 203 differed. To validate the automated Holter recording measurements, >15% of total Holter recordings were 204 manually re-evaluated by two raters blinded to genotype using Lepeschkin's method and Bazett's 205 correction<sup>5,29</sup>. The average OT and OTc for every HR interval for each genotype were then assessed for 206 interrater agreement, defined as a difference of  $\leq 10\%$  of the lower measurement, and Bland-Altman 207 analysis was performed. If there was >10% difference between measurements, the average of both 208 measurements was used for analysis. As a second method of validation, all ECGs for individuals in the 209 cohort were included in a replication analysis. The HR, QT, and QTc for each ECG were manually 210 measured by an electrophysiologist blinded to genotype. Linear regression analyses of HR vs QT and 211 QTc for individuals grouped by genotype were then performed.

212

### 213 Outcomes Analysis

214 We used Kaplan-Meier analysis to assess freedom from composite events, defined as 1) requiring a PM or 215 PM/ICD, or 2) having documented sinus pauses greater than 4 seconds, based on age at last follow-up. 216 For the Primary Cohort, this age was defined as age at last cardiology visit. For the IAHCRC Cohort, last 217 follow-up was defined as November 1, 2022, as the database was last updated through October 2022. For 218 those who had a composite event, age was defined as when they required device implantation or first had 219 sinus pauses greater than 4 seconds. For Holter analyses, we only included individuals with Holter data 220 available for review.

221

# 222 Statistical Analysis

223 Statistical analysis was performed using both JMP Pro 17 and Prism 10. Results are reported as mean  $\pm$ 224 standard deviation with 95% confidence intervals unless otherwise noted. A Kruskal-Wallis test with 225 Dunn's post-hoc multiple comparisons or Dunnet's post-hoc comparison to healthy was used for 226 continuous variables with more than two groups. Fisher's exact test was used for nominal variables with 227 more than two groups. Mann-Whitney test was used for continuous variables with two groups. Wilcoxon 228 matched pairs signed rank test was used to compare two groups with paired samples. Simple linear 229 regression analysis was modeled by the equation QT or  $QTC = mHR + b$ , where m is equivalent to slope 230 and b is equivalent to intercept. This analysis was conducted for overall linear regression for each 231 genotype, as well as individual linear regressions for each Holter recording and first diagnostic Holter 232 recording. A mixed model was also used to verify the genotype linear regression and account for repeated 233 measurements from the same individual. The HR, genotype, and interaction between HR and genotype 234 were fixed effects, QT and QTc were outcome variables, and subject number was a random effect with a 235 residual repeated structure. Kaplan-Meier analysis was compared using log-rank test. Significance was set 236 at P=  $0.05$ .

237

238 **RESULTS** 

# 239 Primary Cohort Characteristics

240 To determine the relationship between cardiac repolarization time and HR, we first evaluated individuals 241 with AHC and healthy individuals recruited from Duke University Hospitals. In total, 44 individuals with 242 *ATP1A3*-related phenotypes and 36 healthy individuals were included in the Primary Cohort (**Table 1**). 243 All Holter recordings available in the HScribe<sup>TM</sup> software were utilized. Individuals with  $ATPIA3$ -related 244 phenotypes were grouped based on genotype as follows: ATP1A3-D801N (9 individuals, 25 Holter 245 recordings); ATP1A3 non-D801N (25 individuals, 38 Holter recordings); *ATP1A3* LOF (4 individuals, 9 246 Holter recordings); *ATP1A3* Neg (6 individuals, 9 Holter recordings). In the healthy group, 36 individuals

247 with 57 Holter recordings were included. We found no significant difference in mean age at first 248 diagnostic Holter and biological sex between genotypes (**Table 1**). Overall, <1% of data points from 249 Holter recordings were excluded.

250

251 Individuals with ATP1A3-D801N show blunted QT change to heart rate variability

252 Our group has previously shown that individuals with ATP1A3-D801N have shorter QTc on ECG 253 compared to those with other variants<sup>15</sup>. Similarly, in our cohort, individuals with ATP1A3-D801N had 254 an overall mean QT and QTc on Holter that were significantly lower than that of healthy individuals 255 (302.68  $\pm$  19.27 and 385.60  $\pm$  27.95, vs 341.12  $\pm$  32.36 and 426.96  $\pm$  20.54, respectively; P <0.0001). 256 Further, the mean QTc for ATP1A3-D801N was significantly lower than that of *ATP1A3* LOF and 257 *ATP1A3* Neg. We then investigated HR modulation of QT interval in each group using a linear regression 258 analysis. It is well established that the QT interval increases with reduced HR and decreases with 259 increased  $HR^{4,30}$  and that the OTc, which is corrected for HR, remains relatively constant across a range  $260$  of HRs in healthy individuals<sup>4,5</sup>. We confirmed this observation in our healthy cohort which showed 261 prolonged QT with slower HR and normalization of HR with QTc, demonstrated by a mean slope of HR 262 vs QT of -1.52 and a mean slope of HR vs QTc of 0.22 (**Figures 1 and 2; Table 2**). Conversely, we found 263 that individuals with ATP1A3-D801N exhibited diminished QT prolongation at lower HRs (**Figure 1;**  264 **Figure S1; Table S1**). Specifically, we found that D801N probands had a lower mean linear regression 265 slope than healthy individuals  $(-0.85 \pm 0.46 \text{ vs } -1.52 \pm 0.42)$ , respectively; P <0.0001; **Table 2**). For 266 example, based on our model, at a mean HR of 60 beats per minute (bpm), D801N probands had a QT of 267 335.33ms. Conversely, healthy individuals had a mean QT of 396.64ms (**Table S2**). These results were 268 unique to individuals hosting the D801N variant. For example, individuals in the ATP1A3 non-D801N, 269 *ATP1A3* LOF, and *ATP1A3* Neg genetic subgroups showed a similar QT vs HR relationship to healthy 270 individuals (mean slope -1.24  $\pm$  0.43, -1.41  $\pm$  0.35, -1.41  $\pm$  0.16, respectively, vs -1.52  $\pm$  0.42; P value not 271 significant). Further, each of these genotype groups showed less impairment of QT dynamics compared to 272 ATP1A3-D801N (**Table 2**). To account for different numbers of Holter recordings per individual, this

273 analysis was also replicated using only the first diagnostic Holter and demonstrated a similar relationship 274 (**Figure S2; Table S3**). We then validated the automated QT measurements using manual measurements 275 with 2 independent evaluators blinded to genotype. Again, we observed a blunted response of QT to 276 lower HR in ATP1A3-D801N with strong interrater agreement (see **Supplemental Results; Figures S3-** 277 **S4, Table S4**). An independent validation using manual HR and QT/QTc measurements from clinical 278 ECGs blinded to genotype demonstrated a similar relationship (**Figure S5**).

279 As several variables, including biological sex, can influence cardiac repolarization time<sup>5,31</sup>, we 280 next conducted a sub-analysis to determine whether other variables might influence this finding. We 281 found that females with an *ATP1A3*-related phenotype, and those with ATP1A3 non-D801N variants, had 282 a significantly lower slope for HR vs QT compared to males, although it was a mild physiologic 283 difference. Further, there were no significant differences between male and females in all other groups 284 (**Table S5**). When analyzed by age, there was no significant difference in QT dynamics between 285 individuals younger than 10, 10–20, or older than 20 years old for ATP1A3-D801N or all *ATP1A3*-related 286 phenotypes (**Table S6**). Taken together, these findings suggest that individuals with ATP1A3-D801N 287 have a blunted prolongation of QT at lower HRs, while other genetic subtypes of AHC were more similar 288 to healthy individuals in their QT dynamics.

289

290 Individuals with ATP1A3-D801N show paradoxical shortening of QTc interval at lower heart rates

291 Given the diminished QT shortening with lower HRs demonstrated in the ATP1A3-D801N group, we 292 hypothesized that this group has an accentuated shortening of QTc at low HR when compared to healthy 293 individuals. Indeed, while control individuals demonstrated no significant change in QTc at lower heart 294 rates, we found that ATP1A3-D801N individuals had further shortening of the QTc (**Figure 2; Figure**  295 **S6; Table S1**), demonstrated by a greater mean slope than healthy individuals  $(0.80 \pm 0.51 \text{ vs } 0.22 \pm 0.43$ , 296 respectively; P <0.0001; **Table 2**). For example, at a heart rate of 60bpm, the QTc for ATP1A3-D801N 297 was 356.7ms compared to 415.6ms in healthy individuals (**Table S7**). As with QT, this relationship was 298 similar when replicated using only the first diagnostic Holter recordings for each individual and upon

299 manual measurement validation (**Supplemental Results; Figures S7-S9, Tables S3 and S8**). When 300 linear regression was performed for ECGs, there was also increased shortening of QTc at lower HR for 301 ATP1A3-D801N variant-positive individuals (**Figure S10).** Further, this blunted response was seen 302 equally in both D801N-positive males and females (**Table S9**), and there was no difference in QTc 303 dynamics based on age in individuals with *ATP1A3*-related phenotypes (**Table S10**). In summary, these 304 results suggest that the blunted QT prolongation with slower HR among individuals with ATP1A3- 305 D801N is associated with a paradoxical reduction of QTc at lower HRs compared to healthy controls and 306 all other genetic subtypes of *ATP1A3*-related phenotypes. We conclude that, given the already low QTc 307 at baseline in these individuals, bradycardia causes further reduction in QTc to a markedly abnormal 308 range, exacerbating a known arrhythmic risk factor.

309

310 Individuals with QTc<350ms demonstrate blunted QT prolongation and QTc shortening with bradycardia 311 We then investigated whether the maladaptive QT and QTc response to low HR is an ATP1A3-D801N 312 specific phenomenon, or whether individuals with other *ATP1A3* variants who have short QTc at baseline 313 also have this abnormal response. To do this, we separated individuals with *ATP1A3*-related phenotypes 314 into different groups defined by their baseline QTc on diagnostic ECG. Groups were defined using 315 Gollob's criteria<sup>6</sup>, where normal QTc was between 370-470ms, borderline short QTc was between 350-316 370ms, and short QTc was <350ms. Seven of the 44 patients with *ATP1A3*-related phenotypes had QTc 317 <350ms. Four of these hosted ATP1A3-D801N and the other 3 hosted ATP1A3 non-D801N variants 318 (**Table S11**). None of the individuals with *ATP1A3* LOF, *ATP1A3* Neg, or healthy individuals had QTc 319 <350ms (**Table S11**). We found that those with short diagnostic QTc (<350ms) had a diminished QT 320 prolongation response to HR compared to those with normal QTc (370-470ms), and the slope of HR vs 321 QTc in the short QTc group was significantly greater than that of the normal QTc group (**Figure 3; Table**  322 **S11**). When separated by specific genotype, there was greater impairment of HR vs QT dynamics in 323 ATP1A3-D801N than in ATP1A3 non-D801N for those with QTc <350ms. However, within each 324 genotype, there was no significant difference in QT or QTc dynamics when grouped by baseline QTc (see

325 **Supplemental Results; Tables S12-S13**). Taken together, we found that presence of short QTc of 326 <350ms on diagnostic ECG for all *ATP1A3*-related phenotypes is associated with greater impairment of 327 QT and QTc dynamics. While this effect was independent of genotype, most patients with QTc <350 328 hosted the ATP1A3-D801N variant.

329

330 Individuals with *ATP1A3* variants are predisposed to significant sinus node dysfunction

331 Given the association between bradycardia and QTc shortening, we next determined whether patients  $332$  hosting *ATP1A3* variants were at increased risk of sinus node dysfunction<sup>19</sup>. To do this, we leveraged a 333 large, multinational registry of individuals with AHC and *ATP1A3* genetic variants. The cohort was 334 comprised of 131 individuals who met our inclusion/exclusion criteria: the same 44 individuals from 335 Duke University Medical Center, 86 individuals from the IAHCRC, and 1 individual from BCM 336 previously described in the literature<sup>15</sup>. Of these additional 87 individuals, 31 had available Holter 337 recording measurements. Additional demographic characteristics for individuals from the IAHCRC and 338 BCM are detailed in **Table S14**. We found no difference in sex or age representation among the genetic 339 subgroups (**Table S14**). Individuals with ATP1A3-D801N reached an average maximum HR during 340 Holter monitoring that was significantly lower than healthy individuals (153.94  $\pm$  18.80 vs 176.21  $\pm$ 341 22.52; P <0.0001). Otherwise, there was no significant difference in average minimum HR, mean HR, 342 and ventricular and supraventricular ectopy burden between any of the groups and healthy individuals 343 (**Table 3**). We identified 3 out of 131 individuals who met the composite endpoint of implantation of a 344 PM or PM/ICD or documented sinus pause, with a mean age at follow-up of 15.62 years (maximum of 50 345 years). Among them, 2 out of 3 hosted the D801N variant and the third hosted ATP1A3-S137F. For 346 healthy individuals, *ATP1A3* LOF, and *ATP1A3* Neg, no individuals met the composite endpoint during 347 the follow-up period. This yielded a calculated composite event rate of 0.15%/year/individual for the 348 entire cohort, with a D801N-positive event rate of 0.38%/year/individual (**Figure 4**). Thus, leveraging the 349 largest international cohort to date to explore this endpoint, we concluded that, although the frequency of

350 significant sinus node dysfunction is low, individuals hosting the D801N variant have a greater 351 predisposition to developing it compared to other genetic subtypes.

352

353 Flunarizine may exacerbate the blunted QT response to bradycardia but does not worsen sinus node 354 dysfunction

Given that the standard of care for treatment of AHC involves the use of flunarizine<sup>32,33</sup>, a T-type calcium 356 channel blocker, we next explored whether use of flunarizine was associated with exacerbation of the 357 cardiac phenotype observed, since its impact on the heart is unknown. Of the 131 individuals included, 90 358 were taking flunarizine and there was no significant difference between flunarizine use and the genetic 359 subtypes (**Table S15**). Among them, flunarizine use was not associated with changes in average 360 minimum, mean, or maximum HR for any genotype group when compared to those who were not taking 361 flunarizine (**Table S15**). When exploring the relationship between QT/QTc dynamics and flunarizine, we 362 did find that the overall slope for HR vs QTc was significantly greater for individuals with all *ATP1A3*- 363 related phenotypes taking flunarizine than for those who were not (**Table S15**). Specifically, we found 364 that at a HR of 60 bpm, the mean QTc was 376.97ms among those taking flunarizine versus 402.4ms 365 among those not taking flunarizine. This suggests that flunarizine might be associated with impairment of 366 QT prolongation during periods of bradycardia; however, the physiologic and clinical relevance of this 367 finding is uncertain. When separated by biological sex, the mean slope for HR vs QT among individuals 368 taking flunarizine was significantly lower in females than in males. At 60bpm, the mean QT in females 369 taking flunarizine was 350.9ms versus 366.1ms in males, suggesting that flunarizine shortening of the QT 370 interval might be exacerbated in female patients (**Table S16**). This sex-bias was also observed for all 371 patients with *ATP1A3*-related phenotypes, regardless of flunarizine use (**Tables S5 and S9**). There was 372 no difference in QT/QTc dynamics based on flunarizine use for males (**Table S17**). However, females 373 taking flunarizine had a significantly lower slope for HR vs QT than females who were not (**Table S18**). 374 Taken together, flunarizine may statistically impair QT dynamics during lower HR among specific 375 subgroups of patients, particularly among female individuals. Despite this statistical difference, the

376 overall physiologic impact of flunarizine on the heart remains unclear. This is particularly important as 377 there is a clear role for flunarizine in treating the neurologic manifestations of *ATP1A3*-related disease.

378

### 379 **DISCUSSION**

380 This study expands our understanding of arrhythmia risk in individuals with *ATP1A3*-related diseases, 381 such as AHC. In healthy individuals, the QT interval adapts to changes in HR by shortening when the HR 382 increases and lengthening when the HR decreases<sup>4,30</sup>. When corrected by HR, the QTc remains relatively 383 fixed across a range of HRs among healthy individuals. We demonstrate that individuals with the 384 ATP1A3-D801N variant show impairment of this relationship with decreased prolongation of QT at 385 lower HR, similar to individuals diagnosed with  $SOTS<sup>9,10</sup>$ . This phenomenon has previously been  $386$  described as deceleration-dependent OT interval shortening<sup>34,35</sup>. One mechanistic explanation for this 387 finding is that increased acetylcholine inhibits the proper prolongation of QT when the HR slows<sup>34,36</sup>.  $388$  Additionally, inhibition of autonomic activity has been shown to cause impairment of QT dynamics<sup>37</sup>. 389 Dysautonomia is a minor diagnostic criterion for  $AHC<sup>13</sup>$  and could therefore be an explanation for the 390 findings we describe in ATP1A3-D801N. Overall, we uncover a potential novel mechanism of QT 391 modulation that could increase arrhythmia risk at lower HR, which seems to be based in a myocardial 392 defect. However, the specific details of how autonomic alterations further exacerbate risk is still 393 unknown.

394

395 Correcting QT for HR can be done through a variety of different means<sup>5,38-40</sup>. Previous work has 396 demonstrated limitations to Bazett's correction in effectively normalizing the QTc during bradycardia and 397 tachycardia<sup>41,42</sup>. Importantly, we found that Bazett's correction held for all healthy individual HR ranges, 398 which include most HR ranges in our disease cohorts. Specifically, the slope of mean HR vs mean QTc 399 for healthy individuals was close to zero, indicating effective normalization of the QT for differences in 400 HR (**Figure 2**). From this, we ultimately concluded that the automated Bazett's correction formula was 401 suitable for correcting QT in all groups. In addition, we assessed association of changes in QT and QTc

402 dynamics with factors such as biological sex, age, and flunarizine use. While we found a difference in HR 403 vs QT between males and females, there was no difference in HR vs QTc, suggesting that HR variation 404 might manifest as a difference in QT responsiveness that subsides with QT correction for HR. Age did not 405 seem to have an effect, whereas flunarizine use showed a small effect on HR vs QTc dynamics. However, 406 we see no clear evidence that flunarizine negatively impacts the heart. Moreover, it is the medication of 407 choice for alleviation of neurologic symptoms in AHC, therefore the known benefits are significantly 408 greater than any harms.

409

410 Given the finding that individuals with ATP1A3-D801N have short QTc at baseline<sup>15,16</sup>, which is a known 411 arrhythmia risk<sup>1-3</sup>, we sought to determine the effect of heart rate on this OT abnormality. We found that 412 individuals with *ATP1A3*-related phenotypes who also had a short baseline QTc demonstrated impairment 413 of normal QT dynamics with changing HR, particularly during periods of bradycardia. This results in a 414 shortening of the QTc at lower HR, which exacerbates the short QT phenotype further. It is likely that 415 this is the proarrhythmic trigger for many patients who have had a life-threatening arrhythmic event with 416 *ATP1A3*-related disease. As such, it is critical that patients with AHC, and anyone with an *ATP1A3* 417 mutation, are evaluated by an electrophysiology and cardiovascular genetic specialist to determine their 418 QT/QTc at baseline. This clinical evaluation, when combined with genetic risk assessment, is key to 419 determining the risk for arrhythmias. Furthermore, with increasing knowledge of the cardiac 420 manifestations of AHC, questions arise as to whether these individuals are at risk of sinus node 421 dysfunction requiring PM or ICD implantation. Analysis of our combined cohort shows that sinus node 422 dysfunction is uncommon, with few individuals requiring a device or experiencing significant sinus 423 pauses. While the risk is low, events can be severe when they do occur, and our results indicate a greater 424 event rate in those with ATP1A3-D801N. Thus, it is crucial to universally check and routinely monitor 425 sinus node dysfunction in these individuals through ambulatory monitoring. Further, as sinus bradycardia 426 resulting from sinus node dysfunction might compound the risk in patients with the D801N variant and 427 short QT, this may represent another pro-arrhythmic variable.

428

429 We acknowledge limitations to our study design and methodology. As this is a retrospective study, it is 430 unclear if abnormal QT and QTc dynamics with decreasing HR are directly responsible for arrhythmias in 431 individuals with ATP1A3-D801N. Future directions include exploring rate dependency in human induced 432 pluripotent stem cell cardiomyocytes (iPSC-CMs) from individuals with ATP1A3-D801N to better 433 characterize this mechanism. Additionally, AHC is a rare disease and our cohort is small. As a result, we 434 may be underpowered to detect certain differences. However, this is the largest study to date of Holter 435 recordings from patients with AHC across a multinational registry. Finally, rather than using beat-to-beat 436 data, our study utilizes five-minute averages of HR, QT, and QTc provided by the Holter monitoring 437 software. Although this provides us with less data than would otherwise be available, we were still able to 438 detect a significant difference in relationships between ATP1A3-D801N and healthy.

439

#### 440 **CONCLUSIONS**

441 Overall, our findings support the idea that AHC, and specifically the ATP1A3-D801N variant, can 442 manifest as a cardiac phenotype resembling SQTS. It is important to advise individuals with ATP1A3- 443 D801N, particularly those with very short baseline QTc on ECG, of the risk of arrhythmia with slowed 444 HR, such as during sedation or anesthesia. Currently, there is no treatment for abnormal QT and QTc 445 dynamics, although quinidine has been proposed for patients with  $SQTS^{10}$ . For now, cardiac monitoring 446 during periods of possible low HR is advised.

447

### 448 **ACKNOWLEDGEMENTS**

449 Thank you to all contributors to the IAHCRC. Dr. Andrew Landstrom had full access to all the data in the 450 study and takes responsibility for data integrity and accuracy of data analysis.

451

### 452 **SOURCES OF FUNDING**





518 10. Wolpert C, Schimpf R, Giustetto C, Antzelevitch C, Cordeiro J, Dumaine R, Brugada R, 519 Hong K, Bauersfeld U, Gaita F, Borggrefe M. Further insights into the effect of quinidine 520 in short QT syndrome caused by a mutation in HERG. *J Cardiovasc Electrophysiol*. 521 2005;16:54-58. doi: 10.1046/j.1540-8167.2005.04470.x 522 11. Redpath CJ, Green MS, Birnie DH, Gollob MH. Rapid genetic testing facilitating the 523 diagnosis of short QT syndrome. *Can J Cardiol*. 2009;25:e133-135. doi: 10.1016/s0828- 524 282x(09)70077-7 525 12. Brugada R, Hong K, Dumaine R, Cordeiro J, Gaita F, Borggrefe M, Menendez TM, 526 Brugada J, Pollevick GD, Wolpert C, et al. Sudden Death Associated With Short-QT 527 Syndrome Linked to Mutations in HERG. *Circulation*. 2004;109:30-35. doi: 528 doi:10.1161/01.CIR.0000109482.92774.3A 529 13. Mikati MA, Panagiotakaki E, Arzimanoglou A. Revision of the diagnostic criteria of 530 alternating hemiplegia of childhood. *Eur J Paediatr Neurol*. 2021;32:A4-a5. doi: 531 10.1016/j.ejpn.2021.05.004 532 14. Panagiotakaki E, Gobbi G, Neville B, Ebinger F, Campistol J, Nevšímalová S, Laan L, 533 Casaer P, Spiel G, Giannotta M, et al. Evidence of a non-progressive course of alternating 534 hemiplegia of childhood: study of a large cohort of children and adults. *Brain*. 535 2010;133:3598-3610. doi: 10.1093/brain/awq295 536 15. Moya□Mendez ME, Ogbonna C, Ezekian JE, Rosamilia MB, Prange L, Uz Cdl, Kim JJ, Howard T, Garcia J, Nussbaum R, et al. ATP1A3-Encoded Sodium-Potassium ATPase 537 Howard T, Garcia J, Nussbaum R, et al. ATP1A3-Encoded Sodium-Potassium ATPase 538 Subunit Alpha 3 D801N Variant Is Associated With Shortened QT Interval and 539 Predisposition to Ventricular Fibrillation Preceded by Bradycardia. *Journal of the*  540 *American Heart Association*. 2021;10:e019887. doi: doi:10.1161/JAHA.120.019887 541 16. Jaffer F, Avbersek A, Vavassori R, Fons C, Campistol J, Stagnaro M, De Grandis E, 542 Veneselli E, Rosewich H, Gianotta M, et al. Faulty cardiac repolarization reserve in 543 alternating hemiplegia of childhood broadens the phenotype. *Brain*. 2015;138:2859-2874. 544 doi: 10.1093/brain/awv243 545 17. Masoud M, Prange L, Wuchich J, Hunanyan A, Mikati MA. Diagnosis and Treatment of 546 Alternating Hemiplegia of Childhood. *Current Treatment Options in Neurology*. 547 2017;19:8. doi: 10.1007/s11940-017-0444-7 548 18. Heinzen EL, Swoboda KJ, Hitomi Y, Gurrieri F, Nicole S, de Vries B, Tiziano FD, 549 Fontaine B, Walley NM, Heavin S, et al. De novo mutations in ATP1A3 cause alternating 550 hemiplegia of childhood. *Nat Genet*. 2012;44:1030-1034. doi: 10.1038/ng.2358 551 19. Balestrini S, Mikati MA, Alvarez-Garcia-Roves R, Carboni M, Hunanyan AS, Kherallah 552 B, McLean M, Prange L, De Grandis E, Gagliardi A, et al. Cardiac phenotype in 553 ATP1A3-related syndromes: A multicenter cohort study. *Neurology*. 2020;95:e2866- 554 e2879. doi: 10.1212/WNL.0000000000010794 555 20. Novy J, McWilliams E, Sisodiya SM. Asystole in alternating hemiplegia with de novo 556 ATP1A3 mutation. *European Journal of Medical Genetics*. 2014;57:37-39. doi: 557 https://doi.org/10.1016/j.ejmg.2013.11.003 558 21. Parker LE, Wallace K, Thevathasan A, Funk E, Pratt M, Thamby J, Tran L, Prange L, 559 Uchitel J, Boggs A, et al. Characterization of sedation and anesthesia complications in 560 patients with alternating hemiplegia of childhood. *European journal of paediatric*  561 *neurology : EJPN : official journal of the European Paediatric Neurology Society*. 562 2022;38:47-52. doi: 10.1016/j.ejpn.2022.03.007

563 22. Thamby J, Prange L, Boggs A, Subei MO, Myers C, Uchitel J, ElMallah M, Bartlett-Lee 564 B, Riviello JJ, Mikati MA. Characteristics of non-sleep related apneas in children with 565 alternating hemiplegia of childhood. *Eur J Paediatr Neurol*. 2024;48:101-108. doi: 566 10.1016/j.ejpn.2023.12.002 567 23. Kligfield P, Lax KG, Okin PM. QT interval-heart rate relation during exercise in normal 568 men and women: Definition by linear regression analysis. *Journal of the American*  569 *College of Cardiology*. 1996;28:1547-1555. doi: https://doi.org/10.1016/S0735- 570 1097(96)00351-8 571 24. Tavernier R, Jordaens L, Haerynck F, Derycke E, Clement DL. Changes in the QT 572 interval and its adaptation to rate, assessed with continuous electrocardiographic 573 recordings in patients with ventricular fibrillation, as compared to normal individuals 574 without arrhythmias. *Eur Heart J*. 1997;18:994-999. doi: 575 10.1093/oxfordjournals.eurheartj.a015389 576 25. Merri M, Moss AJ, Benhorin J, Locati EH, Alberti M, Badilini F. Relation between 577 ventricular repolarization duration and cardiac cycle length during 24-hour Holter 578 recordings. Findings in normal patients and patients with long QT syndrome. *Circulation*. 579 1992;85:1816-1821. doi: doi:10.1161/01.CIR.85.5.1816 580 26. Larroude CE, Jensen BT, Agner E, Toft E, Torp-Pedersen C, Wachtell K, Kanters JK. 581 Beat-to-beat QT dynamics in paroxysmal atrial fibrillation. *Heart Rhythm*. 2006;3:660- 582 664. doi: https://doi.org/10.1016/j.hrthm.2006.02.021 583 27. Magnano AR, Holleran S, Ramakrishnan R, Reiffel JA, Bloomfield DM. Autonomic 584 nervous system influences on qt interval in normal subjects. *Journal of the American*  585 *College of Cardiology*. 2002;39:1820-1826. doi: doi:10.1016/S0735-1097(02)01852-1 586 28. Moya-Mendez ME BM, Zhang Z, Ezekian JE, Perelli RM, Parker LE, Prange L, Boggs 587 A, et al. ATP1A3 Variants are Associated with Variably Penetrant Short QT and Lethal 588 Ventricular Arrhythmias. *In submission* 2024. 589 29. LEPESCHKIN E, SURAWICZ B. The Measurement of the Q-T Interval of the 590 Electrocardiogram. *Circulation*. 1952;6:378-388. doi: doi:10.1161/01.CIR.6.3.378 591 30. Ahnve S. Correction of the QT interval for heart rate: review of different formulas and 592 the use of Bazett's formula in myocardial infarction. *Am Heart J*. 1985;109:568-574. doi: 593 10.1016/0002-8703(85)90564-2<br>594 31. Merri M, Benhorin J, Alberti M, 594 31. Merri M, Benhorin J, Alberti M, Locati E, Moss AJ. Electrocardiographic quantitation of 595 ventricular repolarization. *Circulation*. 1989;80:1301-1308. doi: 10.1161/01.cir.80.5.1301 596 32. Mikati MA, Kramer U, Zupanc ML, Shanahan RJ. Alternating hemiplegia of childhood: 597 clinical manifestations and long-term outcome. *Pediatr Neurol*. 2000;23:134-141. doi: 598 10.1016/s0887-8994(00)00157-0 599 33. Casaer P, Azou M. Flunarizine in alternating hemiplegia in childhood. *Lancet*. 600 1984;2:579. doi: 10.1016/s0140-6736(84)90794-3 601 34. Gussak I, Liebl N, Nouri S, Bjerregaard P, Zimmerman F, Chaitman BR. Deceleration-602 dependent shortening of the QT interval: a new electrocardiographic phenomenon? *Clin*  603 *Cardiol*. 1999;22:124-126. doi: 10.1002/clc.4960220213 604 35. Takahashi N, Ito M, Ishida S, Nakagawa M, Hara M, Saikawa T, Sakata T. Paradoxically 605 shortened QT interval after a prolonged pause. *Pacing Clin Electrophysiol*. 606 1998;21:1476-1479. doi: 10.1111/j.1540-8159.1998.tb00221.x



#### **TABLES**



**Table 1. Primary cohort characteristics.** 

\*Includes individuals with a formal diagnosis of AHC ( $n=37$ ) or CAPOS ( $n=1$ ), those who did not meet full criteria for AHC but were found to host an *ATP1A3* variant (n=5), and one individual with no variant in *ATP1A3* who did not meet full criteria for AHC (n=1). †Includes individuals with deletion (n=3) or splice site variant in  $ATPIA3$  (n=1).  $\ddagger$ Includes individuals with no pathogenic or likely pathogenic variant in *ATP1A3* identified (n=6). P values were calculated using Fisher's exact test or Kruskal-Wallis test. LOF, loss of function variant; Neg, genotype negative.



### **Table 2. Mean slope of linear regression for HR versus QT and QTc, compared by genotype.**

\*Healthy compared to ATP1A3-D801N, using Kruskal-Wallis test with Dunnet's post-hoc comparison to healthy. Values listed as mean  $\pm$  SD (95% confidence interval). HR, heart rate; QTc, corrected QT; LOF, loss of function variant; Neg, genotype negative.



**Table 3. Holter recording characteristics for all individuals from primary and IAHCRC cohorts.** 

Heart rates are listed in beats per minute (BPM), RR is listed in seconds. \*Listed as median (interquartile range), as one individual had 1102 VE per hour (23157 total). P value calculated with Fisher's exact test or Kruskal-Wallis test with Dunn's post-hoc multiple comparisons. HR, heart rate; VE, ventricular ectopy; SVE, supraventricular ectopy; LOF, loss of function variant; Neg, genotype negative.

### **FIGURES**

**Figure 1. ATP1A3-D801N is associated with blunted response of QT to lower HR compared to healthy.** Linear regression analysis of mean HR versus mean QT over five-minute intervals throughout each Holter recording for individuals in the primary and healthy cohorts. Colored points represent individual data points for all Holter recordings included in each genotype group. Solid line represents overall linear regression line of fit. m represents slope of the line of fit equation. A. Healthy cohort  $(n=57)$ , QT= -1.64HR + 501.40; R<sup>2</sup>= 0.70. B. ATP1A3-D801N subgroup (n=25), QT= -0.79HR + 381.50;  $R^2 = 0.32$ . C. ATP1A3 non-D801N subgroup (n=38), QT= -1.27HR + 445.10;  $R^2 = 0.45$ . D. *ATP1A3* LOF subgroup (n=9), QT= -1.28HR + 465.50; R<sup>2</sup>= 0.61. E. *ATP1A3* Neg subgroup (n=9), QT= -1.44HR + 483.80;  $R^2 = 0.80$ . F. Overall lines of fit for each of the respective subgroups. Blue, healthy; black, ATP1A3-D801N; red, ATP1A3 non-D801N; purple, *ATP1A3* LOF; orange, *ATP1A3* Neg.

**Figure 2. ATP1A3-D801N is associated with increased shortening of QTc at lower HR compared to healthy.** Linear regression analysis of mean heart rate versus mean QTc over five-minute intervals throughout Holter recording for individuals in the primary and healthy cohorts. Colored points represent individual data points for all Holter recordings included in each genotype group. Solid line represents overall linear regression line of fit. m represents slope of the line of fit equation. A. Healthy ( $n=57$ ), QT $c=$ 0.06HR + 421.80;  $R^2 = 0.0023$ . B. ATP1A3-D801N (n=25), QTc= 0.96HR + 291.40;  $R^2 = 0.30$ . C. ATP1A3 non-D801N (n=38), QTc= 0.42HR + 362.10; R<sup>2</sup>= 0.055. D. ATP1A3 LOF (n=9), QTc= 0.41HR + 390.40;  $R^2$  = 0.083. E. ATP1A3 Neg (n=9), QTc= 0.28HR + 406.30;  $R^2$  = 0.093. F. Lines of fit for all groups. Blue, healthy; black, ATP1A3-D801N; red, ATP1A3 non-D801N; purple, *ATP1A3* LOF; orange, *ATP1A3* Neg.

**Figure 3. Short baseline QTc is associated with greater impairment of QT and QTc dynamics.** Each colored line represents the linear regression for Holter recordings from individuals in the primary and healthy cohorts with a given baseline QTc on ECG. A. Mean HR versus mean QT for Holter recordings from individuals with *ATP1A3*-related phenotypes (n=81) compared to healthy patients (n=57). B. Mean HR versus mean QTc for Holter recordings from individuals with *ATP1A3*-related phenotypes (n=81) compared to healthy  $(n=57)$ . Black, <350ms  $(n=16)$ ; red, 350-370ms  $(n=15)$ ; purple, 370-470ms  $(n=50)$ ; blue, healthy, all 370-470ms (n=57).

**Figure 4. ATP1A3-D801N is associated with sinus node dysfunction**. A. Kaplan-Meier analysis of freedom from composite events versus age of event in individuals from primary and IAHCRC cohorts  $(n=131)$ , as compared to those from the healthy cohort  $(n=36)$ . Tick marks represent censored individuals. Bars represent 95% confidence intervals. No significant difference between healthy and *ATP1A3*-related phenotype using log-rank test ( $P = 0.57$ ). B. Characteristics of individuals who had composite events. PM, pacemaker; ICD, implantable cardioverter defibrillator.